Search research articles
Contact Us
Filters
Showing results (151-160 of 178) with videos related to
Page
of 18
Sort By:
Hemasphere
|
April 18, 2025
A German multicenter real-world analysis of talquetamab in 138 patients with relapsed/refractory multiple myeloma
Jan H Frenking, Christine Riedhammer, Raphael Teipel, et al.
Nature Medicine
|
July 1, 2026
Clinical decision support in hematological malignancies using a case-grounded AI agent
Julian Zoller, Michael Kalz, Xuewei Wu, et al.
Nature Communications
|
November 29, 2024
Multiple myeloma long-term survivors exhibit sustained immune alterations decades after first-line therapy
Raphael Lutz, Florian Grünschläger, Malte Simon, et al.
Nature Genetics
|
August 20, 2025
Temporal genomic dynamics shape clinical trajectory in multiple myeloma
Francesco Maura, Marcella Kaddoura, Alexandra M Poos, et al.
Hemasphere
|
October 15, 2025
European Myeloma Network Group Consensus Statement on the use of next-generation sequencing for prognostic stratification of newly diagnosed multiple myeloma
Niccolò Bolli, Mattia D'Agostino, Tina Bagratuni, et al.
Biorxiv : the Preprint Server for Biology
|
September 16, 2024
Temporal Genomic Dynamics Shape Clinical Trajectory in Multiple Myeloma
Francesco Maura, Marcella Kaddoura, Alexandra M Poos, et al.
The Lancet. Haematology
|
November 3, 2022
Addition of isatuximab to lenalidomide, bortezomib, and dexamethasone as induction therapy for newly diagnosed, transplantation-eligible patients with multiple myeloma (GMMG-HD7): part 1 of an open-label, multicentre, randomised, active-controlled, phase 3 trial
Hartmut Goldschmidt, Elias K Mai, Uta Bertsch, et al.
Blood Cancer Journal
|
October 20, 2025
Prospective systematic classification of causes of death in the course of multiple myeloma
Jia Xiang Jin, Britta Besemer, Büsranur Yilmaz, et al.
The Lancet. Haematology
|
February 1, 2024
Elotuzumab, lenalidomide, bortezomib, dexamethasone, and autologous haematopoietic stem-cell transplantation for newly diagnosed multiple myeloma (GMMG-HD6): results from a randomised, phase 3 trial
Elias K Mai, Hartmut Goldschmid, Kaya Miah, et al.
Science Immunology
|
February 7, 2025
Bone marrow breakout lesions act as key sites for tumor-immune cell diversification in multiple myeloma
Raphael Lutz, Alexandra M Poos, Llorenç Solé-Boldo, et al.
Page
of 18
Search research articles
Search
Showing results (151-160 of 178) with videos related to
Sort By:
Page
of 18
Hemasphere
|
April 18, 2025
A German multicenter real-world analysis of talquetamab in 138 patients with relapsed/refractory multiple myeloma
Jan H Frenking, Christine Riedhammer, Raphael Teipel, et al.
Nature Medicine
|
July 1, 2026
Clinical decision support in hematological malignancies using a case-grounded AI agent
Julian Zoller, Michael Kalz, Xuewei Wu, et al.
Nature Communications
|
November 29, 2024
Multiple myeloma long-term survivors exhibit sustained immune alterations decades after first-line therapy
Raphael Lutz, Florian Grünschläger, Malte Simon, et al.
Nature Genetics
|
August 20, 2025
Temporal genomic dynamics shape clinical trajectory in multiple myeloma
Francesco Maura, Marcella Kaddoura, Alexandra M Poos, et al.
Hemasphere
|
October 15, 2025
European Myeloma Network Group Consensus Statement on the use of next-generation sequencing for prognostic stratification of newly diagnosed multiple myeloma
Niccolò Bolli, Mattia D'Agostino, Tina Bagratuni, et al.
Biorxiv : the Preprint Server for Biology
|
September 16, 2024
Temporal Genomic Dynamics Shape Clinical Trajectory in Multiple Myeloma
Francesco Maura, Marcella Kaddoura, Alexandra M Poos, et al.
The Lancet. Haematology
|
November 3, 2022
Addition of isatuximab to lenalidomide, bortezomib, and dexamethasone as induction therapy for newly diagnosed, transplantation-eligible patients with multiple myeloma (GMMG-HD7): part 1 of an open-label, multicentre, randomised, active-controlled, phase 3 trial
Hartmut Goldschmidt, Elias K Mai, Uta Bertsch, et al.
Blood Cancer Journal
|
October 20, 2025
Prospective systematic classification of causes of death in the course of multiple myeloma
Jia Xiang Jin, Britta Besemer, Büsranur Yilmaz, et al.
The Lancet. Haematology
|
February 1, 2024
Elotuzumab, lenalidomide, bortezomib, dexamethasone, and autologous haematopoietic stem-cell transplantation for newly diagnosed multiple myeloma (GMMG-HD6): results from a randomised, phase 3 trial
Elias K Mai, Hartmut Goldschmid, Kaya Miah, et al.
Science Immunology
|
February 7, 2025
Bone marrow breakout lesions act as key sites for tumor-immune cell diversification in multiple myeloma
Raphael Lutz, Alexandra M Poos, Llorenç Solé-Boldo, et al.
Page
of 18